Improving Clinical Trials of Antioxidants in Alzheimer's Disease
Timothy Daly1,2
1Science Norms Democracy UMR 8011, Sorbonne Université, Paris, France.
Abstract:
Maintaining diversity in drug development in research into Alzheimer's disease (AD) is necessary to avoid over-reliance on targeting AD neuropathology. Treatments that reduce or prevent the generation of oxidative stress, frequently cited for its causal role in the aging process and AD, could be useful in at-risk populations or diagnosed AD patients. However, in this review, it is argued that clinical research into antioxidants in AD could provide more useful feedback as to the therapeutic value of the oxidative stress theory of AD. Improving comparability between randomized controlled trials (RCTs) is vital from a waste-reduction and priority-setting point of view for AD clinical research. For as well as attempting to improve meaningful outcomes for patients, RCTs of antioxidants in AD should strive to maximize the extraction of clinically useful information and actionable feedback from trial outcomes. Solutions to maximize information flow from RCTs of antioxidants in AD are offered here in the form of checklist questions to improve ongoing and future trials centered around the following dimensions: adhesion to reporting guidelines like CONSORT, biomarker enrichment, simple tests of treatment, and innovative trial design.
Insights
Antioxidant treatments targeting oxidative stress may benefit Alzheimer's disease (AD) patients. Improving clinical trial design and data collection is crucial for evaluating antioxidant therapies and advancing AD research.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Alzheimer's disease (AD) research requires diverse approaches beyond neuropathology.
- Oxidative stress is implicated in aging and AD, suggesting antioxidant interventions as a potential therapeutic strategy.
Purpose of the Study:
- To review the role of antioxidants in Alzheimer's disease (AD) research.
- To advocate for improved clinical trial methodologies to maximize information extraction and therapeutic evaluation of antioxidants.
Main Methods:
- Review of existing literature on antioxidant research in AD.
- Analysis of the challenges in current randomized controlled trials (RCTs) for AD therapies.
- Proposal of solutions to enhance data quality and comparability in AD clinical trials.
Main Results:
- Clinical research on antioxidants could validate the oxidative stress theory of AD.
- Current RCTs in AD may not yield optimal therapeutic insights.
- Standardized reporting, biomarker enrichment, simplified treatment testing, and innovative designs can improve trial outcomes.
Conclusions:
- Diverse drug development strategies are essential for Alzheimer's disease (AD).
- Antioxidant therapies warrant further investigation, contingent on improved clinical trial design.
- Enhanced RCTs will provide actionable feedback on the efficacy of targeting oxidative stress in AD.
More Related Videos
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:26Atherosclerosis III: Management
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists